Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial

Abstract

Objectıve: The aim of the study is to investigate the effect of myo-inositol (MYO) on pregnancy rates of patients diagnosed with polycystic ovary syndrome (PCOS) who undergone controlled ovulation induction and intrauterine insemination (IUI).

Methods: A total of 196 infertile patients diagnosed with PCOS and admitted to Dokuz Eylul University Faculty of Medicine were included in the study between March 2013 and May 2016. The patients in group 1 (n = 98) were given 4 g MYO and 400 μg folic acid before and during ovulation induction. The patients undergone controlled ovarian hyperstimulation (COH) with recombinant FSH and IUI. The patients in group 2 (n = 98), were given recombinant FSH directly and 400 μg folic acid. The primary outcome measure of this study was the clinical pregnancy rate.

Results: In group 1, 9 patients conceived spontaneous pregnancy. During COH + IUI treatment three cycles were canceled in group 1 and 8 cycles in group 2. Total rFSH dose and cycle duration were significantly lower and clinical pregnancy rates were higher in group 1. The pregnancy rate for group 1 was %18.6 and for group 2 was %12.2.

Conclusıons: This study shows that MYO should be considered in the treatment of infertile PCOS patients. MYO administration increases clinical pregnancy rates, lowers total rFSH dose and the duration of the ovulation induction.

Chinese abstract

研究目的：研究肌醇（MYO）对多囊卵巢综合征（PCOS）患者接受促排卵和宫腔内人工授精（IUI）治疗后妊娠率的影响。

研究方法：2013年3月至2016年5月间诊断为PCOS并于DokuzEylul大学医学院接受治疗的196例不育患者被纳入研究。组1（n = 98）患者在促排卵前及促排卵时给予4g MYO和400mg叶酸。患者接受重组FSH超促排卵（COH）行IUI。组2（n = 98）患者直接给予重组FSH和400 mg叶酸。本研究的主要结果指标是临床妊娠率。

结果：第1组9例患者自然怀孕。在COH + IUI治疗期间, 组1取消了3个周期, 组2取消了8个周期。第1组总rFSH剂量明显较低和周期刺激时间明显较短, 而临床妊娠率则较高。第1组的妊娠率为18.6%, 第2组为12.2%。

结论：这项研究表明, 应当考虑在不育PCOS患者中使用MYO治疗。MYO治疗可以增加临床妊娠率, 降低rFSH总剂量, 缩短促排卵时间。

Keywords:

• Infertility
• insulin resistance
• insulin sensitizer
• ovulation induction
• polycystic ovary syndrome

Acknowledgments

No financial relationship with the any organization. Authors have full control of all primary data. All authors contributed significantly and they are in agreement with the content of the manuscript. No conflict of interest.

Declaration of interest

No financial relationship with the any organization. Authors have full control of all primary data. Written informed consent was obtained from the patients for publication. Copies of the written consents are available for review by the Editor-in-Chief of this journal on request. The authors report no conflicts of interest.